Evidence map›Paper›PMID 39198163›Full record

ArticleInternal medicine (Tokyo, Japan)2025

A CML Patient Carrying BCR::ABL1 Splicing Variants Did Not Experience Blast Crisis for 15 Years without Responding to Various TKIs.

Fumi Nakamura, Ko Sasaki, Yasuhito Nannya, Hisako Iso, Yuko Nakamura, Yoichi Imai, Seishi Ogawa, Kinuko Mitani

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fumi NakamuraDepartment of Hematology and Oncology, Dokkyo Medical University, Japan.
Ko SasakiDepartment of Hematology and Oncology, Dokkyo Medical University, Japan.
Yasuhito NannyaDepartment of Pathology and Tumor Biology, Kyoto University, Japan.
Hisako IsoDepartment of Hematology and Oncology, Dokkyo Medical University, Japan.
Yuko NakamuraDepartment of Hematology and Oncology, Dokkyo Medical University, Japan.
Yoichi ImaiDepartment of Hematology and Oncology, Dokkyo Medical University, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University, Japan.
Kinuko MitaniDepartment of Hematology and Oncology, Dokkyo Medical University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 45-year-old man was diagnosed with CML in the chronic phase and therefore was sequentially treated with imatinib, dasatinib, nilotinib, and ponatinib. Neither ABL1 point mutations nor any additional chromosomal abnormalities were detected. The patient's best response was a partial cytogenetic response to nilotinib treatment. The deletion of amino acid residues 184-274 and a 35 bp insertion after nucleotide 1423 of ABL1 were detected before ponatinib administration. Two years after ponatinib administration, the patient died of a traumatic brain hemorrhage 15 years after the CML diagnosis. He did not progress to blast crisis, possibly because of the emergence of a loss-of-function ABL1 splicing variant.

Indexed as

Blast CrisisFusion Proteins, bcr-ablLeukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsDasatinibFatal OutcomeHumansImatinib MesylateImidazolesMaleMiddle AgedPyridazinesPyrimidinesDasatinibFusion Proteins, bcr-ablImatinib MesylateImidazolesponatinibProtein Kinase InhibitorsPyridazinesPyrimidineschronic myeloid leukemiasplicing varianttyrosine kinase inhibitors

Identifiers

PMID39198163
PMCPMC11867739

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.